Free Trial

ADC Therapeutics (ADCT) News Today

ADC Therapeutics logo
$2.76 -0.27 (-8.75%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$2.86 +0.09 (+3.25%)
As of 06/20/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADCT Latest News

ADC Therapeutics SA stock logo
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $5.00 at Royal Bank Of Canada
Royal Bank Of Canada lowered their target price on ADC Therapeutics from $8.00 to $5.00 and set an "outperform" rating for the company in a research note on Friday.
ADC Therapeutics SA stock logo
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $10.00 at Guggenheim
Guggenheim raised their target price on ADC Therapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday.
ADC Therapeutics SA stock logo
Brokers Issue Forecasts for ADCT FY2026 Earnings
ADC Therapeutics SA (NYSE:ADCT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of ADC Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will po
ADC Therapeutics SA stock logo
Wellington Management Group LLP Purchases 84,785 Shares of ADC Therapeutics SA (NYSE:ADCT)
Wellington Management Group LLP raised its position in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) by 50.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 253,342 shares of the company's stock a
ADC Therapeutics SA stock logo
Millennium Management LLC Decreases Stock Position in ADC Therapeutics SA (NYSE:ADCT)
Millennium Management LLC trimmed its holdings in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) by 42.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 411,124 shares of the company's stock after selling 301,277
ADC Therapeutics SA stock logo
Bank of America Corp DE Has $2.57 Million Position in ADC Therapeutics SA (NYSE:ADCT)
Bank of America Corp DE lowered its stake in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) by 48.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,291,244 shares of the company'
ADC Therapeutics SA stock logo
Woodline Partners LP Takes $3.85 Million Position in ADC Therapeutics SA (NYSE:ADCT)
Woodline Partners LP acquired a new stake in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,933,751 shares of the company's stock, valued at approximately
ADC Therapeutics SA stock logo
BNP Paribas Financial Markets Purchases Shares of 716,668 ADC Therapeutics SA (NYSE:ADCT)
BNP Paribas Financial Markets purchased a new stake in ADC Therapeutics SA (NYSE:ADCT - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 716,668 shares of the company's stock, valued at approximately $1,426,000. BNP Paribas Financial Marke
ADC Therapeutics SA stock logo
FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald
ADC Therapeutics SA (NYSE:ADCT - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for ADC Therapeutics in a research note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnin
ADC Therapeutics SA stock logo
Orbimed Advisors LLC Grows Position in ADC Therapeutics SA (NYSE:ADCT)
Orbimed Advisors LLC boosted its holdings in shares of ADC Therapeutics SA (NYSE:ADCT - Free Report) by 31.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,968,451 shares of the c
ADC Therapeutics SA stock logo
ADC Therapeutics (ADCT) Expected to Announce Quarterly Earnings on Monday
ADC Therapeutics (NYSE:ADCT) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-adc-therapeutics-sa-stock/)
ADC Therapeutics SA stock logo
HC Wainwright Analysts Boost Earnings Estimates for ADCT
ADC Therapeutics SA (NYSE:ADCT - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of ADC Therapeutics in a research report issued on Monday, March 31st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.39) per share
ADC Therapeutics SA stock logo
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 14.0%
ADC Therapeutics SA (NYSE:ADCT - Get Free Report) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 4,560,000 shares, a decrease of 14.0% from the February 28th total of 5,300,000 shares. Based on an average daily volume of 514,400 shares, the days-to-cover ratio is currently 8.9 days. Approximately 6.0% of the company's shares are short sold.
ADC Therapeutics SA stock logo
ADC Therapeutics (NYSE:ADCT) Price Target Lowered to $7.00 at Guggenheim
Guggenheim dropped their price objective on shares of ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Monday.
ADC Therapeutics SA stock logo
HC Wainwright Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT)
HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of ADC Therapeutics in a research report on Monday.
ADC Therapeutics SA stock logo
ADC Therapeutics (NYSE:ADCT) Announces Quarterly Earnings Results
ADC Therapeutics (NYSE:ADCT - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.06. The business had revenue of $19.00 million during the quarter, compared to analyst estimates of $19.01 million.
ADC Therapeutics reports Q4 adjusted EPS (25c) vs. (97c) last year
Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

ADCT Media Mentions By Week

ADCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADCT
News Sentiment

0.29

0.67

Average
Medical
News Sentiment

ADCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADCT Articles
This Week

7

2

ADCT Articles
Average Week

Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSE:ADCT) was last updated on 6/23/2025 by MarketBeat.com Staff
From Our Partners